We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Diuretics Best Choice for Treating Hypertension

By HospiMedica staff writers
Posted on 13 Jan 2003
A long-term, multicenter trial that compared diuretics with calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors for lowering blood pressure has shown that diuretics are superior. More...
The results were reported in the December 18, 2002, issue of The Journal of the American Medical Association (JAMA).

The trial also included a cholesterol-lowering study that compared the effects of a statin drug with "usual care.” The difference in cholesterol levels was too small to show a difference in death rates and demonstrated only a nonsignificant decrease in the rate of heart attacks and strokes in the statin group. An arm of the trial included study of an alpha-adrenergic blocker but was stopped because those on the drug had 25% more cardiovascular events and were twice as likely to be hospitalized for heart failure than users of diuretics.

After about five years of follow-up, patients on the calcium channel blocker had 1 mm Hg higher systolic blood pressure and a 38% higher risk of developing heart failure than those taking diuretics. Patients taking ACE inhibitors had 2 mm Hg higher systolic blood pressure, a 15% higher risk of stroke, and a 19% higher risk of developing heart failure.
The study involved more than 42,000 participants with hypertension and at least one other risk factor for heart disease.

The researchers say patients now taking one of the newer medications for hypertension should talk to their doctor. "The new findings will allow doctors to achieve better blood pressure control and, more importantly, better cardiovascular health for their patients. And, they will do this at a more affordable price for their patient,” said Dr. Jeffrey Cutler, senior advisor at the US National Heart, Lung, and Blood Institute (NHLBI) which conducted the trial.




Related Links:
US National Heart, Lung, and Blood Inst.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Syringe Pump
SP50 Series
New
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.